Promising Outlook for Dianthus Therapeutics: Buy Rating Backed by Clinical Progress and Financial Stability

TD Cowen analyst Yaron Werber has maintained their bullish stance on DNTH stock, giving a Buy rating on May 5.

Yaron Werber has given his Buy rating due to a combination of factors including the promising progress of Dianthus Therapeutics’ DNTH103 in treating autoimmune conditions. The company is advancing its clinical trials in generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN), with significant milestones expected in the coming years. The DNTH103, which is an active C1s inhibitor, is being developed with a unique half-life extension technology that allows for more convenient dosing, potentially making it a best-in-class treatment.
Another reason for the Buy rating is the financial stability of Dianthus, with $332 million in cash providing a runway into the second half of 2027. Additionally, the anticipated positive results from Sanofi’s trials with a similar mechanism of action could further validate DNTH103’s potential, enhancing its attractiveness in the market. These factors collectively underpin Werber’s optimistic outlook on the stock.

In another report released on May 5, LifeSci Capital also maintained a Buy rating on the stock with a $45.00 price target.